All In MedTech

Device Trial Radar · NCT03419676

Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy

Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy to Prevent Postoperative Pancreatic Fistula

Last checked: Nov 19, 2026Latest source record: Feb 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

May 1, 2018

Primary completion

Jun 30, 2020

Study completion Feb 10, 2022

Sponsor

Lead sponsor
Hospital Miguel ServetAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aragon Health Science Institute
First posted
Feb 5, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to determine the effect of the sealant patch Hemopatch, compared to current practice without any sealant, on the decrease of the postoperative pancreatic fistula on patients undergoing pancreatoduodenectomy for benign or malignant tumors or other benign process.

Conditions

  • Pancreatic Fistula

Interventions

  • HemopatchDevice

    Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postoperative type B and C pancreatic fistulaTime frame: Up to 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mario Serradilla Martín

    Zaragoza, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.